ORIC Pharmaceuticals Appoints Mardi C. Dier to its Board of Directors
SOUTH SAN FRANCISCO, CA – March 2, 2020 – ORIC Pharmaceuticals, Inc., a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Mardi C. Dier to its board of directors. Ms. Dier currently serves as executive vice president, chief financial officer and chief business officer of Portola Pharmaceuticals, Inc.
“We are delighted to welcome Mardi to ORIC’s board of directors,” said Jacob Chacko, M.D., chief executive officer. “With Mardi’s nearly 20 years of experience as a seasoned biotechnology executive and former investment banker, she brings to ORIC deep relationships with the investment community, coupled with significant financial, strategic, and operational expertise. We look forward to Mardi’s contributions and insights as we advance and expand our pipeline of agents targeting cancer resistance and prepare for our next stage of growth.”
Ms. Dier joined Portola in August 2006 as senior vice president and chief financial officer, has served as executive vice president and chief financial officer since November 2013, and was also appointed chief business officer in October 2018. Ms. Dier is responsible for leading the corporate finance, accounting, information technology, global supply chain, business development, investor relations, and corporate communications functions. During her tenure at Portola, she has successfully led a series of private, public, and alternative financings and helped lead the company through its pivotal transition into a commercial organization. Previously, she served as vice president of investor relations at Chiron Corporation from 2003 until its acquisition by Novartis Pharmaceuticals in 2006. Prior to joining Chiron, she worked as an investment banker at Prudential Securities, where she focused on client development, equity underwriting, and mergers and acquisitions for biotechnology and other life sciences companies, and prior to that was in the audit department of KPMG Peat Marwick. She holds a B.S. in biology from Stanford University and an M.B.A. from the Anderson School at the University of California, Los Angeles.
“I am excited to join ORIC’s board at this critical juncture as the company advances its lead asset, ORIC-101, through two clinical studies and continues to progress a broad pipeline of novel therapies aimed at overcoming resistance in cancer,” said Ms. Dier. “I look forward to working with ORIC’s leadership team, its board, as well as its founders, to provide financial and strategic guidance as the company’s pipeline continues to expand and mature.”
About ORIC Pharmaceuticals
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is headquartered in South San Francisco, California. For more information, please go to http://oricpharma.com/.